2 years ago

MitoRx Therapeutics Raises $4 Million in Seed Extension Funding

  • MitoRx Therapeutics, a UK-based biotechnology company, secured an undisclosed amount in additional seed funding, bringing the total to $4 million

  • The round was led by UK Innovation & Science Seed Fund and included Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, and angel investors

  • The company will utilize the funds to accelerate preclinical work in HD, activate its first neurodegenerative disease program, and explore research collaborations and partnerships.

      • ProblemHealthcare

      "Mitochondrial dysfunction is a root cause of degenerative diseases, leading to conditions like Duchenne muscular dystrophy (DMD) and Huntington’s disease (HD), causing significant suffering and limited treatment options."

      Solution

      "MitoRx Therapeutics develops orally delivered therapeutics targeting mitochondrial dysfunction, preventing the progression of rare neuromuscular disorders and neurodegenerative diseases, offering hope for patients and families impacted by these debilitating conditions."

      Covered on